Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study

Background Simultaneous measurement of gastrointestinal transit time (GITT) and plasma levodopa concentration (PLC) is crucial to understanding the effect of dysfunctional motility on levodopa response in patients with Parkinson's disease (PwPD). Objective The aim is to determine if altered segmental GITT correlates with clinical response and PLC variability in PwPD. Methods Ten typical and 10 erratic responders ingested the SmartPill (SP) wireless motility capsule. Serial PLC and finger tapping, obtained every 30 minutes for 3 hours after SP/levodopa ingestion, evaluated the correlation between GITT, clinical response, and PLC. Glucose breath testing assessed small intestinal bacterial overgrowth (SIBO). Results GITT was not significantly different in typical and erratic responders. SIBO was positive in half of the erratic and negative in most typical responders. Conclusion SP is a feasible technology for assessing GITT in PwPD. A larger study may be able to significantly differentiate/correlate GITT in different segments of the GI tract with response to levodopa. (c) 2022 International Parkinson and Movement Disorder Society.

Automated summary

This study aimed to investigate whether altered segmental gastrointestinal transit time (GITT) correlates with clinical response and plasma levodopa concentration (PLC) variability in patients with Parkinson's disease. The results showed no significant difference in GITT between typical and erratic responders. Additionally, Small Intestinal Bacterial Overgrowth (SIBO) was positive in half of the erratic responders and negative in most typical responders.